Stereotactic Ablative Radiation Therapy for Oligo-Progressive Non Small Cell Lung Cancer

Official Title

Stereotactic Ablative Radiation Therapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial


A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiation therapy to all oligoprogressive lesions while continuing their current systemic therapy.

Trial Description

Primary Outcome:

  • PFS
  • OS
Secondary Outcome:
  • Quality of life Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE)
  • Quality of life 5-level EQ-5D (EQ-5D-5L)
  • Grade ≥ 3 toxicity
  • Local control
  • Time to next systemic therapy

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society